July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Elvina Almuradova: The SERENA-6 Trial Introduces a New Standard in ESR1-mutant ER+/HER2- Advanced Breast Cancer
Jun 2, 2025, 21:29

Elvina Almuradova: The SERENA-6 Trial Introduces a New Standard in ESR1-mutant ER+/HER2- Advanced Breast Cancer

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:

“ASCO25 — The SERENA-6 trial introduces a new standard in ESR1-mutant ER+/HER2- advanced breast cancer.
Camizestrant, a next-gen oral SERD, significantly prolonged PFS (16.0 vs 9.2 months) when switched at molecular progression (via ctDNA), before radiologic progression.
  • Improved quality of life
  • Low discontinuation rate
  • Better tolerated than AIs
A compelling move toward molecular response–guided therapy in first-line ER+ MBC.”

Elvina Almuradova: The SERENA-6 Trial Introduces a New Standard in ESR1-mutant ER+/HER2- Advanced Breast Cancer

Read OncoDaily’s Special Articles about ASCO 2025:

15 Posts Not to Miss from the 1st Day of ASCO 2025

15 Posts Not to Miss from the 2nd Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

15 Posts Not to Miss from the 4thDay of ASCO 2025